Protagonist Therapeutics
Update in progressPTGX (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Protagonist Therapeutics, Inc. is a U.S. discovery and development company focused on novel therapies. It is advancing Icotyde, an oral peptide for adults and children 12+ with moderate-to-severe plaque psoriasis; Rusfertide, a hepcidin-mimetic in Phase 3 for polycythemia vera. It is also developing PN-881 (IL-17 antagonist) in early trials, PN-477 and PN-458 for obesity, PN-8047, L-4R alpha antagonist, and amylinR-based obesity agents. Founded 2006, based in Newark, California.
Company score
- Sentiment
- 0.57
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.30
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.34
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!